跳至主要内容
临床试验/IRCT20210609051526N2
IRCT20210609051526N2招募中3 期

Effect of Empagliflozin on Liver Enzymes level in type two Diabetic Patients with Non-Alcoholic Steatohepatitis

Babol University of Medical Sciences0 个研究点目标入组 110 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 85 years(—)
性别
All

入选标准

  • Body mass index less than 35 Kg/mm
  • No history of chronic alcohol usage
  • No history of viral hepatities
  • No history of autoimmune hepatitis
  • No history of drug-induced hepatitis
  • No history of chronic usage of hepatic-steatosis-induced drugs(e.g.: Amiodarone, Valproate, Tamoxifen, Methotrexate, Glucocorticoids)
  • No history of chronic usage of Thiazolidines and GLP-1 agonists
  • Absence of evidence suggestive for cirrhosis based on physical examination, laboratory evaluation, and imaging studies
  • Absence of evidence suggestive for Hepatocellular carcinoma based on physical examination, laboratory evaluation, and imaging studies
  • Non pregnant women
  • No previous history of HELLP syndrome in women
  • No history of chronic kidney disease
  • No history of chronic usage of Omega-3 containing supplements
  • No contraindication for Empagliflozin usage (e.g.: history of recurrent genitourinary tract infection, gangrene, history of allergic reaction to the drug, serum Trigliceride level more than 500 mg/dl)

排除标准

  • 未提供

研究者

相似试验